Regeneron Pharmaceuticals (REGN) Q1 2025 Earnings
Regeneron Pharmaceuticals reported Q1 2025 revenue of $3.0B (-3.7% YoY), missed analyst consensus of $3.2B by $219.3M. Diluted EPS came in at $8.22 (-13.9% YoY), missed the $8.62 consensus by $0.40. Regeneron Pharmaceuticals reports across 4 business segments, led by Ophthalmology, Immunology & Inflammation, and Oncology.
Financial Snapshot
Trailing eight quarters through Q1 2025
Q1 2025 Earnings FAQ
Common questions about Regeneron Pharmaceuticals's Q1 2025 earnings report.
Regeneron Pharmaceuticals (REGN) reported Q1 2025 earnings on April 29, 2025 before market open.
Regeneron Pharmaceuticals reported revenue of $3.0B and diluted EPS of $8.22 for Q1 2025.
Revenue missed the consensus estimate of $3.2B by $219.3M. EPS missed the consensus estimate of $8.62 by $0.40.
Compared to the same quarter a year prior, revenue declined 3.7% from $3.1B a year earlier and diluted EPS declined 13.9% from $9.55.
You can read the 10-Q periodic report (0001804220-25-000022) directly on SEC EDGAR. The filing index links above go to sec.gov.